These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34117839)

  • 1. Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy.
    Zhou Q; Zhou Y; Li T; Ge Z
    Macromol Biosci; 2021 Aug; 21(8):e2100133. PubMed ID: 34117839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-Mediated STING Activation for Cancer Immunotherapy.
    Li Y; Li X; Yi J; Cao Y; Qin Z; Zhong Z; Yang W
    Adv Healthc Mater; 2023 Jul; 12(19):e2300260. PubMed ID: 36905358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING activation in cancer immunotherapy.
    Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
    Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Nanovaccine Targeting Clec9a
    Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
    Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unlocking the promise of systemic STING agonist for cancer immunotherapy.
    Sun X; Zhou X; Lei YL; Moon JJ
    J Control Release; 2023 May; 357():417-421. PubMed ID: 37001564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
    Garland KM; Sheehy TL; Wilson JT
    Chem Rev; 2022 Mar; 122(6):5977-6039. PubMed ID: 35107989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving STING Agonist Delivery for Cancer Immunotherapy Using Biodegradable Mesoporous Silica Nanoparticles.
    Park KS; Xu C; Sun X; Louttit C; Moon JJ
    Adv Ther (Weinh); 2020 Oct; 3(10):. PubMed ID: 34295963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING-Activating Small Molecular Therapeutics for Cancer Immunotherapy.
    Huang C; Tong T; Ren L; Wang H
    Chembiochem; 2024 Oct; 25(19):e202400255. PubMed ID: 38980259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
    Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
    Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity.
    Endo R; Ueda T; Nagaoki T; Shima N; Sato Y; Harashima H; Nakamura T
    J Control Release; 2024 Aug; 372():609-618. PubMed ID: 38942082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
    Hines JB; Kacew AJ; Sweis RF
    Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanodelivery of STING agonists against cancer and infectious diseases.
    Zhou J; Ventura CJ; Fang RH; Zhang L
    Mol Aspects Med; 2022 Feb; 83():101007. PubMed ID: 34353637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of small molecule inhibitors/agonists targeting STING for disease.
    Liu K; Lan Y; Li X; Li M; Cui L; Luo H; Luo L
    Biomed Pharmacother; 2020 Dec; 132():110945. PubMed ID: 33254439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional STING-Activating Mn
    Zhou M; Wang X; Lin S; Cheng Y; Zhao S; Lin J; Fang Z; Lou Z; Qin L; Wei H
    Adv Healthc Mater; 2020 Jul; 9(13):e2000064. PubMed ID: 32484320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.
    Wu JJ; Zhao L; Hu HG; Li WH; Li YM
    Med Res Rev; 2020 May; 40(3):1117-1141. PubMed ID: 31793026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A next-generation STING agonist MSA-2: From mechanism to application.
    Yang J; Luo Z; Ma J; Wang Y; Cheng N
    J Control Release; 2024 Jul; 371():273-287. PubMed ID: 38789087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
    Xuan C; Hu R
    ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020).
    Chen NN; Zhang H; You QD; Xu XL
    Expert Opin Ther Pat; 2021 Jun; 31(6):563-584. PubMed ID: 33459063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
    Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
    Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives.
    Huang C; Shao N; Huang Y; Chen J; Wang D; Hu G; Zhang H; Luo L; Xiao Z
    Mater Today Bio; 2023 Dec; 23():100839. PubMed ID: 38024837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.